Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments falls 76.9% from a year ago
Short-term investments stood at $28.76M at the end of Q1 FY2026, down 76.9% from a year earlier and down 54.3% from the prior quarter. Over 3 fiscal years it compounded at +386.8% a year.
Context
- Short-term investments amounted to 29.2% of total assets at the end of Q1 FY2026, down 50.3 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -76.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 62.98M USD
- Year-over-year change
- +423.8%
- 3-year CAGR
- +386.8%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.98M | +423.8% |
| FY2024 | 2024-12-31 | 12.02M | +4633.1% |
| FY2023 | 2023-12-31 | 254K | -53.5% |
| FY2022 | 2022-12-31 | 546K | — |
Short-term Investments vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 short-term investments of $28.76M is the 9th highest of the 11 companies compared; the peer median is $80.94M.
- Its year-over-year change of -76.9% is the 7th highest of 8, against a peer median of -39.9%.
- Short-term investments amounts to 29.2% of total assets for AARD, versus a peer median of 50.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $195.48M | +189.1% | +69.1% | 83.0% | |
| Mar 2026 | $128.85M | -3.2% | -8.6% | 40.9% | |
| Mar 2026 | $105.57M | -41.0% | -12.5% | 70.9% | |
| Mar 2026 | $95.97M | -39.9% | -35.7% | 43.2% | |
| Mar 2026 | $81.24M | -23.0% | +9.2% | 45.7% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $80.64M | — | — | 55.3% |
| Mar 2026 | $57.01M | — | — | 57.1% | |
| Mar 2026 | $35.25M | -62.0% | — | 54.8% | |
| Mar 2026 | $28.76M | -76.9% | +386.8% | 29.2% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding AARD) | $80.94M | -39.9% | -8.6% | 50.3% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.